ZA201404199B - Compositions, comprising improved il-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same. - Google Patents

Compositions, comprising improved il-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same.

Info

Publication number
ZA201404199B
ZA201404199B ZA2014/04199A ZA201404199A ZA201404199B ZA 201404199 B ZA201404199 B ZA 201404199B ZA 2014/04199 A ZA2014/04199 A ZA 2014/04199A ZA 201404199 A ZA201404199 A ZA 201404199A ZA 201404199 B ZA201404199 B ZA 201404199B
Authority
ZA
South Africa
Prior art keywords
immunotherapeutics
vaccines
compositions
methods
improved
Prior art date
Application number
ZA2014/04199A
Other languages
English (en)
Inventor
Matthew P Morrow
Jian Yan
David B Weiner
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of ZA201404199B publication Critical patent/ZA201404199B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/00114—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA2014/04199A 2011-12-12 2014-06-06 Compositions, comprising improved il-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same. ZA201404199B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161569600P 2011-12-12 2011-12-12
PCT/US2012/069017 WO2013090296A1 (en) 2011-12-12 2012-12-11 Compositions, comprising improved il-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same

Publications (1)

Publication Number Publication Date
ZA201404199B true ZA201404199B (en) 2015-08-26

Family

ID=48613120

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2014/04199A ZA201404199B (en) 2011-12-12 2014-06-06 Compositions, comprising improved il-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same.

Country Status (12)

Country Link
US (4) US9272024B2 (enExample)
EP (2) EP2791157A4 (enExample)
JP (5) JP6333730B2 (enExample)
KR (5) KR102445129B1 (enExample)
CN (1) CN104245719B (enExample)
AU (1) AU2012352457B2 (enExample)
BR (1) BR112014014078A2 (enExample)
CA (1) CA2858893A1 (enExample)
EA (1) EA026926B1 (enExample)
MX (2) MX354986B (enExample)
WO (1) WO2013090296A1 (enExample)
ZA (1) ZA201404199B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX354986B (es) * 2011-12-12 2018-03-28 Univ Pennsylvania Composiciones que comprenden construcciones geneticas y vacunas de il-12 mejoradas, agentes inmunoterapeuticos y metodos para su uso.
US9669091B2 (en) 2013-03-15 2017-06-06 Inovio Pharmaceuticals, Inc. Vaccines having an antigen and interleukin-23 as an adjuvant
MX383277B (es) * 2015-01-09 2025-03-13 Oncosec Medical Inc Plasmido que codifica a un agonista coestimulador.
EP3173092B1 (en) 2015-04-22 2019-06-26 CureVac AG Rna containing composition for treatment of tumor diseases
DK3458083T5 (da) 2016-05-18 2024-10-21 Modernatx Inc Polynukleotider, der koder for interleukin-12 (il12), og anvendelser heraf
US20190336552A1 (en) 2016-05-30 2019-11-07 Astellas Pharma Inc. Genetically engineered vaccinia viruses
PT3480307T (pt) 2016-05-30 2021-07-26 Nat Univ Corp Tottori Univ Novos vírus da vacina geneticamente modificados
CN106520779A (zh) * 2016-11-09 2017-03-22 华南农业大学 一种通过密码子优化鸡il‑2基因提高鸡的il‑2蛋白表达效率的方法
US11421011B2 (en) 2017-05-18 2022-08-23 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
MX2021003539A (es) 2018-09-26 2021-05-27 Astellas Pharma Inc Terapia contra el cancer en donde el virus vaccinia oncolitico e inhibidor de punto de control inmunitario se usan en combinacion, y composicion farmaceutica y medicamento de combinacion usado en ella.
SG11202103192RA (en) 2018-10-03 2021-04-29 Xencor Inc Il-12 heterodimeric fc-fusion proteins
KR102524247B1 (ko) * 2018-12-21 2023-04-21 가톨릭대학교 산학협력단 p40-EBI3의 복합체 및 이의 용도
GB2606844B (en) 2019-09-18 2025-08-06 Aldevron Llc Synthetic DNA vectors and methods of use
WO2021067863A2 (en) 2019-10-03 2021-04-08 Xencor, Inc. Targeted il-12 heterodimeric fc-fusion proteins
KR20220114531A (ko) * 2019-10-24 2022-08-17 이노비오 파마수티컬즈, 인크. 재발성 호흡기 유두종증을 위한 개선된 백신 및 이를 사용하는 방법
CN110777115B (zh) * 2019-11-21 2020-08-21 北京启辰生生物科技有限公司 用于促进辅助T细胞产生TNF-α细胞因子的工程化DC细胞及方法
EP4181957A4 (en) 2020-07-20 2024-08-07 Deka Biosciences, Inc. TWO-CYTOKINE FUSION PROTEIN COMPRISING IL-10
KR20240156653A (ko) * 2021-12-13 2024-10-30 데카 바이오사이언시즈, 인크. 다중-서브유닛 시토카인을 포함하는 이중 시토카인 융합 단백질
JP2025503454A (ja) * 2021-12-17 2025-02-04 ウィリアム マーシュ ライス ユニバーシティ Ｉｌ－１２を発現するカプセル化細胞及びその使用
CN116535491B (zh) * 2022-05-06 2024-03-22 珠海丽凡达生物技术有限公司 治疗性核酸分子、混合物、药物及在治疗实体瘤中的应用
CN119256082A (zh) * 2022-05-27 2025-01-03 北京天一方生物科技发展有限公司 一种恒定地产生IL-12p70的增殖性髓样细胞的制备方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077044A (en) 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US5223424A (en) 1985-09-06 1993-06-29 Prutech Research And Development Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence
US5310668A (en) 1986-06-20 1994-05-10 Merck & Co., Inc. Varicella-zoster virus as a live recombinant vaccine
US5242829A (en) 1986-09-23 1993-09-07 Therion Biologics Corporation Recombinant pseudorabies virus
IL86583A0 (en) 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
US5294441A (en) 1987-06-04 1994-03-15 Washington University Avirulent microbes and uses therefor: salmonella typhi
US5387744A (en) 1987-06-04 1995-02-07 Washington University Avirulent microbes and uses therefor: Salmonella typhi
US5112749A (en) 1987-10-02 1992-05-12 Praxis Biologics, Inc. Vaccines for the malaria circumsporozoite protein
US5225336A (en) 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
AT400955B (de) 1989-03-08 1996-05-28 Health Research Inc Rekombinantes pockenvirus-wirtsselektionssystem
WO1990011687A1 (en) 1989-03-31 1990-10-18 Washington University VACCINES CONTAINING AVIRULENT phoP-TYPE MICROORGANISMS
ES2070997T3 (es) 1989-12-04 1995-06-16 Akzo Nobel Nv Virus de herpes recombinante de pavos y vacunas vector vivas derivadas de los mismos.
US5294548A (en) 1990-04-02 1994-03-15 American Biogenetic Sciences, Inc Recombianant Hepatitis a virus
US5462734A (en) 1990-11-02 1995-10-31 Wisconsin Alumni Research Foundation Bovine herpesvirus vaccine and method of using same
US5240703A (en) 1991-03-01 1993-08-31 Syntro Corporation Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof
WO1993024640A2 (en) 1992-06-04 1993-12-09 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
WO1994016737A1 (en) 1993-01-26 1994-08-04 Weiner David B Compositions and methods for delivery of genetic material
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
CA2268276A1 (en) * 1996-10-18 1998-04-30 Jeff Nordstrom Gene expression and delivery systems and uses
IL132103A0 (en) 1997-04-03 2001-03-19 Eletrofect As Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
DE69826124T3 (de) 1997-06-30 2007-10-11 Institut Gustave Roussy Verabreichung der nukleinsäure in den quergestreiften muskel
CA2323604A1 (en) * 1998-03-19 1999-09-23 Valentis, Inc. Interferon alpha plasmids and delivery systems, and methods of making and using the same
EP2428250A1 (en) 1998-07-13 2012-03-14 Genetronics, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US20030181405A1 (en) * 1999-03-12 2003-09-25 Nordstrom Jeffrey L. Interferon alpha plasmids and delivery systems, and methods of making and using the same
JP3543326B2 (ja) 2001-08-30 2004-07-14 ソニー株式会社 情報処理装置および方法、情報処理システム、情報配信装置、記録媒体、並びにプログラム
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
CA2504593C (en) 2002-11-04 2016-08-09 Advisys, Inc. Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells
DK1628749T3 (da) 2003-05-30 2019-09-16 Vgxi Inc Anordninger og fremgangsmåder til biomateriel produktion
KR20060031610A (ko) * 2003-05-30 2006-04-12 유니버시티 오브 사우스 플로리다 악성 종양 치료 방법
US7833754B2 (en) * 2006-01-13 2010-11-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services IL-12 for expression in mammalian cell
US8586055B2 (en) * 2007-01-12 2013-11-19 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services DNA immunization protocols
AU2010241864B2 (en) * 2009-04-30 2014-02-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible interleukin-12
MX354986B (es) * 2011-12-12 2018-03-28 Univ Pennsylvania Composiciones que comprenden construcciones geneticas y vacunas de il-12 mejoradas, agentes inmunoterapeuticos y metodos para su uso.
GB2504774A (en) 2012-08-10 2014-02-12 Munster Simms Eng Ltd Diaphragm pump with integral motor housing and rear pump housing
TWI548337B (zh) 2015-10-16 2016-09-01 技嘉科技股份有限公司 散熱模組、顯示卡組件及電子裝置

Also Published As

Publication number Publication date
WO2013090296A1 (en) 2013-06-20
JP6803354B2 (ja) 2020-12-23
KR20200042960A (ko) 2020-04-24
AU2012352457B2 (en) 2016-04-21
EP3336096A1 (en) 2018-06-20
HK1205130A1 (zh) 2015-12-11
EA026926B1 (ru) 2017-05-31
BR112014014078A2 (pt) 2018-10-09
MX2014006987A (es) 2014-11-10
KR20140110934A (ko) 2014-09-17
JP2024138373A (ja) 2024-10-08
JP7129106B2 (ja) 2022-09-01
US9272024B2 (en) 2016-03-01
CN104245719B (zh) 2016-09-14
JP6333730B2 (ja) 2018-05-30
JP2022160704A (ja) 2022-10-19
CA2858893A1 (en) 2013-06-20
US20150004188A1 (en) 2015-01-01
KR102101819B1 (ko) 2020-04-21
MX2020001385A (es) 2020-03-20
US20160235840A1 (en) 2016-08-18
US20220193230A1 (en) 2022-06-23
CN104245719A (zh) 2014-12-24
KR20240096837A (ko) 2024-06-26
EP2791157A1 (en) 2014-10-22
KR102445129B1 (ko) 2022-09-20
JP2018134100A (ja) 2018-08-30
AU2012352457A1 (en) 2014-07-03
KR102674807B1 (ko) 2024-06-13
BR112014014078A8 (pt) 2017-06-13
US9981036B2 (en) 2018-05-29
JP2015501840A (ja) 2015-01-19
KR102277469B1 (ko) 2021-07-15
KR20220132652A (ko) 2022-09-30
JP2021042245A (ja) 2021-03-18
US11241496B2 (en) 2022-02-08
EA201491171A1 (ru) 2014-09-30
EP2791157A4 (en) 2015-10-14
KR20210089272A (ko) 2021-07-15
US20180333485A1 (en) 2018-11-22
MX354986B (es) 2018-03-28

Similar Documents

Publication Publication Date Title
IL274798B (en) Ph20 polypeptide variants, formulations and uses thereof
BR112014014078A8 (pt) composições compreendendo constructos genéticos il-12 aperfeiçoados e vacinas, imunoterapêuticos e métodos de uso dos mesmos
EP2855680B8 (en) Compositions and methods for silencing gene expression
EP2747767B8 (en) Certain chemical entities, compositions, and methods
IL237625A0 (en) Antibodies against m-cam, preparations containing them and their uses
IL227625A0 (en) Nanoparticle compounds, their formulations, and their use
IL222467A0 (en) Certain amino-pyrimidines, compositions thereof, and methods for their use
IL222465A (en) Certain amino-pyridazines, their compositions and methods of use
SMT202000603T1 (it) Formulazione di rna per immunoterapia
IL229208A0 (en) Antibodies against 2-masp, preparations containing them and their uses
IL235004A0 (en) Antibodies against fgfr2, preparations containing them and their uses
EP2530079A4 (en) PHENYL-C-GLUCOSIDE DERIVATIVES, PREPARATION METHODS AND USES THEREOF
PL2768936T3 (pl) Preparaty, ich zastosowanie jako środków do zmywania naczyń lub do wytwarzania środków do zmywania naczyń i ich wytwarzanie
GB2489187B (en) Compositions, methods and related uses for cleaving modified DNA
EP2670763A1 (en) Certain chemical entities, compositions, and methods
EP2705166A4 (en) METHOD AND COMPOSITIONS FOR COMPLETE ISOTHERMIC GENOMAMPLIFICATION
EP2933250A4 (en) PHENYL-C-GLUCOSIDE DERIVATIVE CONTAINING DEOXYGLUCOSE STRUCTURE, PREPARATION METHOD AND USE THEREOF
IL232383A0 (en) Antibodies against kdr, preparations containing them and their uses
EP3442497B8 (en) Active combinations, compositions and methods for enhancing hair growth
EP2753174A4 (en) PARTICULAR CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
ZA201404826B (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
PH12012501548A1 (en) Compositions comprising sugar-cysteine products
PL3427723T3 (pl) Preparat rna do immunoterapii
Reicher et al. Culture of Shock
AU2013348363B2 (en) Terminally modified RNA